Abstract. Hepatocellular carcinoma (HCC) is a huge threat for human health worldwide. As a complicated tumor, the molecular basis for HCC development especially metastasis requires exploration. Although RNA binding motif (RBM) proteins are closely related to various cancers, the clinical importance and underlying mechanisms of RBM8A in HCC remain elusive. In this study, we found that RBM8A was highly expressed in HCC tumor tissues compared to normal liver tissues. Overexpression of RBM8A was associated with HbsAg and Edmondson pathological grading. Moreover, Kaplan-Meier survival analysis showed that high expression of RBM8A was related to the poor overall survival and progression-free survival of patients with HCC. Gain-and loss-of-function experiments further demonstrated that RBM8A promoted tumor cell migration and invasion in HCC via activation of epithelial-mesenchymal transition signaling pathway. It is also noteworthy that RBM8A is required for tumor cell proliferation and anti-apoptosis in HCC. Altogether, our results revealed a close relationship between RBM8A and HCC prognosis as well as a critical tumor-promoting function of RBM8A in HCC progression, suggesting that RBM8A might be a potential bio-marker and drug target in HCC therapy.
Introduction
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver with over 500,000 people affected. HCC is now the third leading cause of cancer deaths worldwide which attracts intensive research (1) . The occurrence and development of HCC is a complex process involving multi-genes, multi-steps and multi-stages. The invasion and metastasis of HCC is closely linked with HCC patient's treatment and prognosis (2) . Thus, it is of great significance to reveal HCC specific genes and investigate the mechanism of aberrant molecules in the occurrence and development of HCC.
The recently identified RNA-binding motif protein 8A (RBM8A, also known as Y14) belongs to the RNA-binding motif protein (RBM) family (3) . Scientists have focused on this protein family for its diverse functions. These proteins bind to RNA and tightly control gene expression, cell cycle, apoptosis and RNA splicing (4) (5) (6) (7) (8) . RBM8A is a vital apoptosis regulator and loss of RBM8A leads to increased apoptosis. Ishigaki et al (9) found that loss of RBM8A inhibited the proliferation of HeLa and A549 cells and cells were blocked at M phase. Importantly, they found the abnormal centrosome in cancer cells, which is a symbolic feature of apoptosis, indicating the loss of RBM8A directly regulate cell apoptosis. Moreover, downregulated RBM8A led to decreases of pro-apoptotic genes such as Bcl-Xs belonging to Bcl-2 family, Bim and Mcl1S (10, 11) . These studies showed that PBM8A participated in various steps of apoptosis. Evidence also demonstrated that RBM8A control tumor occurrence and development via regulating mRNA splicing.
The function of RBM8A in HCC is poorly understood. Although Zindy et al (12) found that RBM8A was upregulated in liver cancer as a target gene of re-establishment of extracellular matrix, metabolism and post-transcription regulation, the function of RBM8A in HCC remain largely unknown. Hence, we analyzed the expression level of RBM8A in patient HCC tumor samples and evaluated the relationship of RBM8A expression level and clinicopathological factors and prognosis. We further explored the function of RBM8A in HCC tumor cell migration, invasion as well as apoptosis.
Materials and methods
Patient data. A total of 105 surgical tissue samples of HCC were collected from patients at Affiliated Tumor Hospital of Guangxi Medical University after obtaining the subject informed consent and institutional review board approval.
Cell lines. The human HCC cell lines were purchased from Stem Cell Bank, Chinese Academy of Sciences. Bel-7404, High expression of RBM8A predicts poor patient prognosis and promotes tumor progression in hepatocellular carcinoma and HL-7702 cells were maintained in Dulbecco's modified Eagle's medium (DMEM). MHCC97H, a high-metastatic human HCC, was established as reference (13) . The media were supplemented with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA), penicillin (100 U/ml), and streptomycin (100 µg/ml) in a humidified atmosphere of 5% CO 2 at 37˚C. All the cells were confirmed to be free from mycoplasma contamination. The cycling conditions were as initial denaturation at 95˚C for 5 min, and then 36 cycles of denaturation at 95˚C for 10 sec and annealing at 60˚C for 30 sec. The relative mRNA expression was calculated using the comparative Ct (∆∆Ct) method.
Establishment
Wound-healing assay. The in vitro migration ability of HCC cells was assessed by wound-healing assay. Cells were plate in 6-well plates and the monolayer was artificially scratched with 10-µl pipette tips. The wound areas were photographed 0 and 20 h after scratching and measured using a caliper. The wound-closure percentages were calculated using the following formula: [1-(current wound size/initial wound size)] x100.
Cell invasion assay. Cells were detached and re-suspended in a serum-free medium and seeded on the upper chamber of Matrigel-coated Transwell inserts with a pore size of 8 µm. The culture medium containing 10% FBS as a chemoattractant was added to the lower chamber. After 24 h incubation, the cells on the upper surface of the insert were gently removed with a cotton swab. Invading cells (lower surface of the insert) were fixed with 4% paraformaldehyde (Sigma-Aldrich), stained with crystal violet, and counted under a microscope. Five random microscopic fields were examined for each insert.
Cell Counting assay. The Bel7404 and BL7702 cells were seeded into 96-well culture plates (5x10 3 cells/well). At 24, 48, 72 and 96 h, 10 µl CCK-8 reagent (Beyotime Biotechnology) was added to each well and incubated for 4 h. Then the absorbance values were read at a wavelength of 450 nm using a microplate reader (SpectraMax 250; GE Healthcare Life Sciences, Pittsburgh, PA, USA).
Flow cytometry analysis. Cells were seeded into 6-well plates at a density of 1x10 6 cells/well for 24 h. Subsequently, the cells were collected and stained with the ANXA5 (Annexin V)-PE apoptosis detection kit (4A Biotech Co. Ltd., FXP018-100) according to the manufacturer's instructions and analyzed by flow cytometry (FACS Calibur, BD Biosciences, San Jose, CA, USA).
Statistical analyses. Unless stated otherwise, data are presented as mean ± SD in the figures. A Student t-test was Table I . Quantification of RBM8A protein levels in HCC tissues, adjacent tissues and normal non-carcinoma tissues. performed to compare the in vitro data. The Kaplan-Meier survival analysis was generated using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA). One-way analysis of variance was initially performed to determine whether overall statistically significant changes occurred before using two-tailed paired or unpaired Student's t-tests. Multiple test-adjusted P-values of <0.05 were considered statistically significant. All statistical tests were two-sided.
Results

RBM8A is upregulated in hepatocellular carcinoma.
In order to explore the function of RBM8A in hepatocellular carcinoma (HCC), we first detected the expression of RBM8A in normal liver tissues, carcinoma adjacent tissues and HCC tissues. Of note, we found that the mRNA level of RBM8A was significantly higher in HCC (7.99±5.49) compared to carcinoma adjacent tissues (4.66±3.78) as well as normal liver tissues (1.64±1.53). We also noted that the mRNA level of RBM8A in carcinoma adjacent tissue was significantly higher than normal liver tissues (Fig. 1A) . The western blotting results showed that RBM8A protein was detectable in all tissues and the protein level of RBM8A was consistently higher in HCC tissues (1.86±0.36) compared to carcinoma adjacent tissues (1.35±0.32) as well as normal liver tissues (0.95±0.35) demonstrating that RBM8A was upregulated in HCC ( Fig. 1B and Table I ).
To further validate the expression differences, we performed immunohistochemistry (IHC) against RBM8A on normal liver tissue, carcinoma adjacent tissue and HCC tissue. As shown in Fig. 1C , strong positive signals were observed in HCC samples with a positive rate of 87.6%. Statistical analysis results indicated that RBM8A IHC signals were significantly higher in carcinoma tissues and signals in carcinoma adjacent tissue were also higher than normal liver tissue (Table II) .
Relationships between RBM8A expression levels with clinical indexes and survival. To further investigate the relationship between RBM8A expression levels with clinical indexes at both mRNA and protein levels, we set the relative mRNA expression level 7.99 as a limit and divided the 105 cases into RBM8A mRNA high group and RBM8A mRNA low group. There were 85 cases in the RBM8A mRNA high group with IHC positive while 20 cases in the RBM8A mRNA low group. Noteworthy, our results revealed significant differences of RBM8A protein levels with different HBsAg levels, tumor diameters, TNM staging and Edmondson pathological grading.
We observed significant correlations between RBM8A high group with HBsAg, Edmondson pathological grading and TMN stages (Table III) . However, no significant differences between RBM8A mRNA levels with tumor diameter and TNM staging. Thus, our result showed that at both mRNA and protein level, high level of RBM8A were associated with HBsAg and Edmondson pathological grading. Non-parametric rank correlation analysis between RBM8A protein expression and Edmondson pathological grading (Table IV) . Among the 105 cases, the follow-up periods varies from 3 days to 620 days without loss. All cases were fitted into the analysis and the follow-up rate was 100%. We divide all cases into RBM8A protein high group (IHC staining: positive and strong positive, n=64) and RBM8A protein low group (IHC: staining weak positive and negative, n=41). By applying Kaplan-Meier survival curve, we calculated overall survival and progression-free survival and tested the statistic difference with Log-rank test. Our results showed that median of overall survival for RBM8A high expression group and RBM8A low expression group were 160 and 229 days, respectively, while median of progression-free survival for RBM8A high expression group and RBM8A low expression group were 90 and 114 days, respectively (Fig. 2) . Both overall survival and progression-free survival in RBM8A low expression group were significantly longer than that in RBM8A high expression group indicating that patients with higher RBM8A expression are expecting shorter survival time.
Knockdown of RBM8A reduces cell migration and invasion. We next validated the results in human normal hepatic immortalized cell line and HCC cell lines. As expected, we found that RBM8A expressions were abundant in HCC cell lines Bel-7404 and MHCC-97H (Fig. 3A) . On the contrary, RBM8A exhibited a low protein level in human hepatic immortalized cell line HL-7702. To further elucidate the function of RBM8A, we generated a set of shRNAs to knock down RBM8A in Bel-7404 cell line. Our results revealed that one of the shRNAs targeting 5'-AGAGCATTCACAAACTGAA-3' was able to reduce the mRNA of RBM8A by more than 80% (Fig. 3B) .
Additionally, the protein level of RBM8A was also effectively downregulated with this shRNA while RBM8A was successfully rescued in Bel-7404 (Fig. 3C) . To investigate the effect of RBM8A on cell migration and invasion, control cells, RBM8A knockdown cells and RBM8A rescued Bel-7404 cells were analyzed by migration assay. Our results showed that the migration of HCC cells were significantly reduced upon RBM8A knockdown while the RBM8A rescued group regained migration ability ( Fig. 3D and E) . We next applied gain of function experiment by overexpressing RBM8A in HL-7702 cell line. Both mRNA and protein level of RBM8A were significantly increased in HL-7702 RBM8A-OE cells (Fig. 4A and B) . Moreover, the invasion ability of HCCs positively associated with the expression levels of RBM8A. (Fig. 4C and D) . Thus, our results demonstrated that RBM8A promotes cell migration and invasion in HCC cells.
RBM8A regulates HCC cell epithelial-mesenchymal transition.
In order to elucidate the underlying mechanisms of RBM8A-mediated HCC migration and invasion, we investigated the epithelial-mesenchymal transition (EMT) markers and related signaling. We found a significant reduction of Snail and phosphorylated STAT3 in RBM8A knockdown Bel-7404 while unphosphorylated STAT3 remained stable indicating that EMT was impaired upon RBM8A knockdown (Fig. 5A ). We noted a clear reduction of EMT markers fibronectin and vimentin in RBM8A knockdown Bel-7404 cells which also suggested a reduction of EMT (Fig. 5A) . On the contrary, in RBM8A overexpressed HL-7702 cells, we observed an increase of Snail and phosphorylated STAT3 as well as fibronectin and vimentin (Fig. 5B) compared with control cells. Furthermore, immunofluorescence staining validated our western blotting results (Fig. 5C) . All above results support that RBM8A is responsible for the epithelial-mesenchymal transition of HCC cells.
RBM8A has an important function in HCC cell survival.
To further explore the role RBM8A plays in HCC cell, we examined whether RBM8A regulate cell proliferation in HCC cells. Noteworthy, our results displayed that knockdown of RBM8A in Bel-7404 cells significantly reduced the population of HCC after three days of cultivation while, ectopic expression of RBM8A in HL-7202 cells significantly increased the HCC population ( Fig. 6A and B) . Since RBM8A is a vital apoptosis regulator and loss of RBM8A leads to increased apoptosis (16), we examined the HCC apoptosis upon RBM8A knockdown or RBM8A overexpression. Accordingly, our FACS results showed a marked increase of apoptotic cells when RBM8A was knocked down in Bel-7404 (Fig. 6C) . However, the number of apoptotic cells was greatly reduced in ectopic expression of RBM8A in HL-7202 cell line (Fig. 6D) .
Taken together, our results demonstrated that high expression of RBM8A can predict poor patient prognosis and promote tumor progression in HCC cells. 
Discussion
RBM8A is an RNA binding protein with molecular weight of 26 kDa locating at chromosome 14q21-q23. The gene codes four transcripts and expresses broadly within the cell and shuffles between the nuclear and cytoplasm (14) . Compared to other RNA binding motif proteins, the structure and molecular function of RBM8A is poorly understood. The known biological function is that RBM8A could participate in forming the exon-junction binding complex (EJC) (15) . RBM8A is the core factor of nonsense-mediated mRNA decay (NMD) and participates in the NMD-mediated mRNA surveillance. NMD keeps the stability of mRNA by degrading the abnormal mRNA products with premature termination codons and reduces the production of harmful shortened proteins (16) (17) (18) . In 2001, Noensie and Dietz proposed the use of siRNA or drugs to inhibit NMD and in turn to identify mutated genes and treat the tumor (19) . Since it has been proposed that the development of malignant tumor is closely related to mRNA stability; it is possible to discover new routes to treat cancer by interfering with the NMD of malignant tumors. As the core factor of NMD, RBM8A may play an essential role during cell malignant transformation.
RBM8A is found highly expressed in malignant tumors such as primary liver cancer, pleural endotheliomas, multiple myeloma and other malignant tumors (3, 11, 12, (20) (21) (22) (23) . Further analysis revealed that the function of RBM8A could be that the knockdown of RBM8A in lung adenocarcinoma resulted in cell cycle arrest in G2/M phase. RBM8A-Mago complex mediated the location of centrosome which further inhibited the mitosis of tumor cells and then induced apoptosis (9, 24) . Moreover, as the core factor of EJC complex, loss of RBM8A led to downregulation of the apoptotic genes Bcl-xS in Bcl-2 family and Mcl1 and resulted in loss of apoptotic control and further induced the metastasis of hepatocellular carcinoma (HCC) (2, 10) . Ras/MAPK, JAK/STAT3 and NF-κB signaling pathways are confirmed to be closely related to occurrence, development, invasion and metastasis of liver cancer (25) (26) (27) . Loss of RBM8A led to changes of all these signaling pathways (23, (28) (29) (30) : loss of RBM8A led to reduction of MAPK protein and inhibited Ras/MAPK signaling pathway which resulted in cell apoptosis; loss of RBM8A resulted in inhibition of JAK/ STAT3 signaling pathway and prohibited bindings between DNA and STAT3; loss of RBM8A also led to decrease of phosphorylation of TNF-α/STAT3 signaling pathway and reduced the effect of NF-κB. As a common factor of these three signaling pathways, RBM8A protein plays vital roles in inhibiting cell growth and apoptosis. Our results also indicated that RBM8A inhibited apoptosis and loss of RBM8A would clearly prevent invasion and metastasis. Our data showed that EMT signaling pathways were affected upon RBM8A demonstrating that the stability of invasion and metastasis was disrupted due to abnormal EMT process.
Our studies revealed from both in vivo and in vitro level that RBM8A is significantly increased in HCC and could be used as a diagnostic marker for HCC. One of the mechanisms of malignant tumor occurrence is the high mutation frequency of oncogenes. These mutations induce NMD pathway and result in pre-inhibition of oncogene translation. The high expression of RBM8A in HCC tissues verified that NMD pathway is highly active in liver cancer tissues indicating that PTC mutation is higher compared to normal tissues. Furthermore, additional study is required to prove whether micro-metastasis exists and causes differentially expressed RBM8A.
RBM8A expression is associated with HbsAg expression level. Epidemiology results revealed that hepatitis B virus infection is the most critical factor of HCC in China. Almost all the hepatitis B virus-associated liver cancers contain hepatitis B virus integration and the integrated virus promoted the development of liver fibration and liver cell inflammation and in turn promoted the occurrence of liver cancer (31, 32) . Our result found that significantly high expression of RBM8A at both mRNA and protein level in HbsAg positive group indicating that RBM8A participates in the integration of HbsAg gene and interacts with hepatitis B virus surface antigen and promotes the occurrence of liver cancer.
Clinical grading and clinical TNM staging are vital for clinical evaluation of liver cancer and provide great significance for prognosis (33) . Our results showed that RBM8A expression is higher in late stage liver cancer than early stage liver cancer. In histology, lower liver cancer pathological grading corresponds to higher RBM8A expression level. Kim et al (21) , confirmed that cervical carcinoma patients with lymphatic metastasis possessed higher RBM8A expression than patients without lymphatic metastasis indicating that RBM8A could serve as a molecular marker for liver cancer early diagnosis and metastasis evaluation.
We divided clinical cases into RBM8A high expression level group and RBM8A low expression level group based on IHC results and followed up these cases. Our results showed that median of overall survival are 160 and 229 days, respectively, while median of progression-free survival for RBM8A high expression group and RBM8A low expression group are 90 and 114 days, respectively, indicating that RBM8A could serve as a marker for liver cancer prognosis since RBM8A is closely related to reoccurrence, migration and overall survival.
In summary, our results demonstrated that RBM8A is highly expressed in HCC. RBM8A displayed significant differences in different HBsAg expression, tumor diameter, TNM staging and Edmondson pathological grading which guides pathological and clinical conclusion. Additionally, we found that patients with lower RBM8A expression level had longer OS and PFS. Besides, our results indicate that RBM8A promotes invasion and metastasis via EMT signaling pathway.
Loss of RBM8A significantly induces apoptosis and reduces tumor cell population demonstrating that RBM8A could serve as a potential target for clinical treatment.
